Icon

TOPAMAX (nda020505)- (25MG,50MG,100MG,200MG,300MG,400MG)

TOPIRAMATE JANSSEN PHARMS
25MG,50MG,100MG,200MG,300MG,400MG
Yes No
2016-Apr-13 Expired
None None
None No
TOPAMAX  is indicated for: • Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older • Preventive treatment of migraine in patients 12 years of age and older
13 0 8
Total Other Developers 3
Drugs with Suitability No
25MG ** ** Up - 7
50MG ** ** Up - 7
100MG ** ** Up - 7
200MG ** ** Up - 7
300MG ** ** - - -
400MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 8
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** *** ***** ******* *********** **** *-*, *-**, *-** **** ********** ****, ******** *******, ******-*****, ****, *********** ******, ***** (***) ***
****** ***** *** ***** ******* *** *********** **********, *** ****** ****, *********, ********* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** ** *-*, ******* ********** ******, *******-******,, ***, ** ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ****** **. ***, *** *** ***, ******* ***** *. *. **. ** *******-*******, ******-****** *********, *********, ******* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ****** ******** ****** ******* ******* *** *********** ****-*, ****** **. ***, ***, ***, *** ** *** ******** *******, ********* ******, **********, ********* ******, ***** (***) ***
****** ******* ****** ******* ***************, *** *********** * **** ***., *********, *** **** (**) *****, ****** ****** (***) ***
****** ******* ****** ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ******* ****** ******* ***************, *** *********** *** * ******** *****, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ******* **** *** ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ******* **** *** ******* ************ ******* *********** **** **. ** ** **, ******* ********** ******, *******, ******, *** ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** ****** ****** *** ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ***** ****** *** *** ****** *************** ******* *********** ****, ****** ****, ******, *********, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.